Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Director departure Appointed director Notes underwriting agrmnt
|
Allarity Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/27/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
08/11/2023 |
8-K
| Quarterly results |
07/27/2023 |
8-K
| Resignation/termination of a director, Appointed a new director |
07/17/2023 |
8-K
| Other Events Interactive Data |
07/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
07/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
|
"Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering BOSTON, MA — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing of its “reasonable best efforts” public offering of 2,444,445 shares of common stock and common warrants to purchase up to 2,444,445 shares of common stock at an effective combined price of $4.50 per share and common warrant for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $4.50 per share, will be exercisable immediately and will expire five years from the initial ..." |
|
07/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
06/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
06/28/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ... |
06/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
05/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
04/25/2023 |
8-K
| Quarterly results |
04/19/2023 |
8-K
| Quarterly results |
03/28/2023 |
8-K
| Quarterly results |
03/20/2023 |
8-K
| Quarterly results |
03/20/2023 |
8-K
| Quarterly results |
03/09/2023 |
8-K
| Investor presentation |
02/28/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu... |
02/10/2023 |
8-K
| Quarterly results |
02/06/2023 |
8-K
| Quarterly results |
01/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Regulation FD Disclosure ... |
01/20/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
|
"Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders Boston, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today announced that the Company’ s 2023 Annual Meeting of Stockholders , on January 19, 2023, at 1:00 p.m. was adjourned without any business being conducted. The Meeting was adjourned until Friday, February 3, 2023, to allow additional time for stockholders to vote on the proposals set forth in the Company’ s definitive proxy statement filed with the U.S. Securities and Exchange Commission on December 6, 2022 . The adjourned Meeting will reconvene on February 3, 2023, at 1:00 p.m. virtually at http..." |
|
01/19/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
01/18/2023 |
8-K
| Quarterly results |
12/21/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
12/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders Interactive... |
12/01/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
11/25/2022 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T... |
11/15/2022 |
8-K
| Quarterly results
Docs:
|
"Allarity Therapeutics Reports Third Quarter 2022 Financial Results Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity’ s cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses: General and Administrative expenses were $1.6 million for the three months ended September 30, 2022, as c..." |
|
10/14/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
10/11/2022 |
8-K
| Quarterly results |
09/30/2022 |
8-K
| Quarterly results |
09/26/2022 |
8-K
| Appointed a new director
Docs:
|
"Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022. Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent director. “I am delighted that Jerry has chosen to join Allarity’ s board at ...",
"UPDATE TO COMPANY OVERVIEW PRESENTATION" |
|
09/12/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Regulation FD Disclosure, Financial Statements and Exhibits I... |
|
|
|